91,671 Shares in Abbott Laboratories $ABT Acquired by NBT Bank N.A.

NBT Bank N.A. purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 91,671 shares of the healthcare product maker’s stock, valued at approximately $9,060,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABT. BlackRock Inc. lifted its position in Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the period. State Street Corp boosted its holdings in shares of Abbott Laboratories by 1.7% during the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after buying an additional 1,350,766 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $1,603,607,000. Deutsche Bank AG grew its position in shares of Abbott Laboratories by 18.6% in the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock worth $1,515,963,000 after buying an additional 2,614,965 shares during the period. Finally, Legal & General Group Plc purchased a new stake in shares of Abbott Laboratories in the 2nd quarter worth about $1,082,524,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 2.1%

Shares of NYSE:ABT opened at $102.64 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a fifty day simple moving average of $105.30 and a two-hundred day simple moving average of $98.28. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The stock has a market capitalization of $177.61 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 1.86 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm had revenue of $13.01 billion for the quarter, compared to analysts’ expectations of $12.99 billion. During the same period in the prior year, the firm posted $1.30 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. On average, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Analyst Upgrades and Downgrades

ABT has been the subject of several research reports. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research note on Thursday, August 13th. Rothschild & Co Redburn raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the company from $119.00 to $127.00 in a research report on Friday, October 2nd. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $118.32.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted EPS of $1.42, in line with the main consensus estimate, and revenue of $13.01 billion, slightly above the $12.99 billion estimate. Reported sales rose 14.5% year over year, while comparable sales increased 7%. Abbott third-quarter results
• Positive Sentiment: Abbott reaffirmed its full-year adjusted EPS guidance, and analysts continue to see upside. Wells Fargo raised its price target to $119, while Robert W. Baird raised its target to $123. Citigroup, RBC, JPMorgan, TD Cowen and BTIG lowered targets but retained bullish ratings, including “buy,” “outperform” or “overweight.”
• Positive Sentiment: The company received European approval for its Cologuard Plus colorectal-cancer screening test, expanding the potential market for its diagnostics portfolio. Abbott Cologuard Plus European approval
• Neutral Sentiment: Abbott plans a tax-free separation of its approximately $8.5 billion Nutrition business into an independent, publicly traded company by the end of 2027. Management says the move could give both businesses more focused investment strategies, but investors face execution, allocation and valuation uncertainty during the transition. Abbott Nutrition separation announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth outlook, citing pressure from diabetes-related pricing and weakness in parts of its electrophysiology and medical-device businesses. This softer outlook overshadowed the quarterly revenue performance and led several analysts to trim price targets. Abbott lowers 2026 sales forecast
• Negative Sentiment: India’s food regulator issued a notice involving infant-formula claims related to Nestlé India and Abbott, creating a limited regulatory overhang for Abbott’s Nutrition operations. India infant-formula regulatory notice

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.